146 related articles for article (PubMed ID: 17925883)
1. Critical assessment of the methylphenidate transdermal system.
Kowalik S; Minami H; Silva RR
Drugs Today (Barc); 2007 Aug; 43(8):515-27. PubMed ID: 17925883
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
3. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
Findling RL; Dinh S
CNS Drugs; 2014 Mar; 28(3):217-28. PubMed ID: 24532028
[TBL] [Abstract][Full Text] [Related]
4. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
5. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
[TBL] [Abstract][Full Text] [Related]
6. Transdermal methylphenidate system: old wine in a new bottle.
Bukstein OG
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
[TBL] [Abstract][Full Text] [Related]
8. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
González MA; Campbell D; Rubin J
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
Silva RR
Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
[No Abstract] [Full Text] [Related]
10. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
[TBL] [Abstract][Full Text] [Related]
11. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
12. Evolution of stimulants to treat ADHD: transdermal methylphenidate.
Patrick KS; Straughn AB; Perkins JS; González MA
Hum Psychopharmacol; 2009 Jan; 24(1):1-17. PubMed ID: 19051222
[TBL] [Abstract][Full Text] [Related]
13. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
Wilens TE; Boellner SW; López FA; Turnbow JM; Wigal SB; Childress AC; Abikoff HB; Manos MJ
J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):700-708. PubMed ID: 18434918
[TBL] [Abstract][Full Text] [Related]
14. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.
Manos M; Frazier TW; Landgraf JM; Weiss M; Hodgkins P
Curr Med Res Opin; 2009 Dec; 25(12):3001-10. PubMed ID: 19849639
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
Heal DJ; Pierce DM
CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study.
Pierce D; Dixon CM; Wigal SB; McGough JJ
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):355-64. PubMed ID: 18759645
[TBL] [Abstract][Full Text] [Related]
17. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
[TBL] [Abstract][Full Text] [Related]
18. Methylphenidate transdermal system.
Mays DA; Findling R
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
[No Abstract] [Full Text] [Related]
19. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
Findling RL; Katic A; Rubin R; Moon E; Civil R; Li Y
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):365-75. PubMed ID: 20973707
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
Pelham WE; Manos MJ; Ezzell CE; Tresco KE; Gnagy EM; Hoffman MT; Onyango AN; Fabiano GA; Lopez-Williams A; Wymbs BT; Caserta D; Chronis AM; Burrows-Maclean L; Morse G
J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):522-9. PubMed ID: 15908834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
